Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Humira is the company’s blockbuster immunology drug, which has faced competition from biosimilars since 2023. North Chicago, Ill.-based AbbVie had a loss per share of 2 cents, due to an ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Of the amount earned in 2024, $1.6 million came from Michael’s salary, which increased a little less than $200,000 compared with 2023 as part of his promotion, AbbVie said in its 2025 proxy ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...